Okechukwu Samuel Ogah, M.Sc.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Nigeria | 37 | 2023 | 731 | 2.180 |
Why?
|
Hypertension | 33 | 2024 | 8455 | 1.860 |
Why?
|
Heart Failure | 23 | 2023 | 10856 | 1.250 |
Why?
|
Stroke | 23 | 2024 | 9963 | 0.850 |
Why?
|
Starvation | 1 | 2022 | 134 | 0.850 |
Why?
|
Perindopril | 4 | 2022 | 12 | 0.780 |
Why?
|
Rheumatic Heart Disease | 5 | 2022 | 177 | 0.730 |
Why?
|
Registries | 14 | 2021 | 8077 | 0.720 |
Why?
|
Cardiovascular Diseases | 9 | 2023 | 15108 | 0.700 |
Why?
|
Urban Population | 4 | 2014 | 2018 | 0.650 |
Why?
|
Africa South of the Sahara | 14 | 2023 | 724 | 0.580 |
Why?
|
Malnutrition | 1 | 2022 | 625 | 0.550 |
Why?
|
Ghana | 12 | 2023 | 287 | 0.540 |
Why?
|
Hypertrophy, Left Ventricular | 10 | 2019 | 859 | 0.520 |
Why?
|
Pulmonary Heart Disease | 1 | 2014 | 36 | 0.500 |
Why?
|
Africa | 11 | 2024 | 670 | 0.500 |
Why?
|
Echocardiography | 14 | 2022 | 5097 | 0.490 |
Why?
|
Amlodipine | 4 | 2022 | 83 | 0.430 |
Why?
|
Hydrochlorothiazide | 4 | 2022 | 98 | 0.430 |
Why?
|
Patient Readmission | 4 | 2018 | 3111 | 0.390 |
Why?
|
Vitamin K | 3 | 2022 | 294 | 0.370 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2022 | 2407 | 0.360 |
Why?
|
Research Design | 3 | 2023 | 5979 | 0.350 |
Why?
|
Prevalence | 14 | 2024 | 15194 | 0.330 |
Why?
|
Diabetes Mellitus | 4 | 2022 | 5724 | 0.320 |
Why?
|
Cardiomyopathy, Dilated | 1 | 2014 | 851 | 0.310 |
Why?
|
Cost of Illness | 2 | 2014 | 1852 | 0.310 |
Why?
|
Risk Factors | 30 | 2024 | 72145 | 0.300 |
Why?
|
Cerebral Hemorrhage | 5 | 2023 | 2643 | 0.290 |
Why?
|
Life Style | 3 | 2021 | 3824 | 0.290 |
Why?
|
Outpatients | 1 | 2014 | 1483 | 0.290 |
Why?
|
Middle Aged | 57 | 2023 | 213127 | 0.290 |
Why?
|
Heart Diseases | 3 | 2011 | 2789 | 0.290 |
Why?
|
Length of Stay | 3 | 2015 | 6294 | 0.280 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 4 | 2022 | 236 | 0.280 |
Why?
|
Blood Pressure | 11 | 2022 | 8541 | 0.270 |
Why?
|
Acute Disease | 9 | 2018 | 7141 | 0.270 |
Why?
|
Cardiomyopathies | 3 | 2023 | 1912 | 0.260 |
Why?
|
Hypertension, Pulmonary | 4 | 2017 | 1527 | 0.250 |
Why?
|
Humans | 91 | 2024 | 742088 | 0.250 |
Why?
|
Male | 61 | 2023 | 349538 | 0.250 |
Why?
|
Atrial Fibrillation | 6 | 2022 | 5019 | 0.250 |
Why?
|
Antihypertensive Agents | 5 | 2022 | 2043 | 0.240 |
Why?
|
Pericarditis, Tuberculous | 2 | 2014 | 6 | 0.240 |
Why?
|
Adult | 46 | 2024 | 213712 | 0.240 |
Why?
|
Female | 58 | 2023 | 379592 | 0.230 |
Why?
|
Ventricular Function, Left | 7 | 2023 | 3656 | 0.220 |
Why?
|
Peripartum Period | 2 | 2021 | 133 | 0.220 |
Why?
|
Inpatients | 1 | 2014 | 2495 | 0.220 |
Why?
|
Coronary Artery Disease | 3 | 2023 | 6454 | 0.220 |
Why?
|
Prednisolone | 2 | 2014 | 333 | 0.220 |
Why?
|
Electrocardiography | 4 | 2017 | 6440 | 0.210 |
Why?
|
Pneumonia, Aspiration | 1 | 2023 | 144 | 0.210 |
Why?
|
Mycobacterium | 2 | 2014 | 249 | 0.210 |
Why?
|
Case-Control Studies | 18 | 2023 | 21719 | 0.200 |
Why?
|
Prognosis | 16 | 2022 | 29010 | 0.200 |
Why?
|
Aged | 36 | 2023 | 162944 | 0.200 |
Why?
|
Prospective Studies | 17 | 2023 | 53187 | 0.200 |
Why?
|
Myocardial Ischemia | 4 | 2021 | 2145 | 0.190 |
Why?
|
Urban Health | 2 | 2014 | 547 | 0.190 |
Why?
|
Gross Domestic Product | 1 | 2021 | 76 | 0.190 |
Why?
|
Arrhythmias, Cardiac | 3 | 2021 | 2267 | 0.190 |
Why?
|
Resistin | 1 | 2021 | 170 | 0.190 |
Why?
|
Prehypertension | 1 | 2021 | 61 | 0.190 |
Why?
|
Cross-Sectional Studies | 9 | 2022 | 24913 | 0.180 |
Why?
|
Economic Recession | 1 | 2021 | 78 | 0.180 |
Why?
|
Heart Valve Diseases | 3 | 2018 | 1067 | 0.180 |
Why?
|
Socioeconomic Factors | 4 | 2021 | 7770 | 0.180 |
Why?
|
Severe Acute Respiratory Syndrome | 1 | 2021 | 137 | 0.180 |
Why?
|
Body Fat Distribution | 1 | 2021 | 244 | 0.180 |
Why?
|
Developing Countries | 5 | 2023 | 2789 | 0.180 |
Why?
|
Ventricular Remodeling | 3 | 2020 | 1224 | 0.180 |
Why?
|
Ecosystem | 1 | 2024 | 471 | 0.180 |
Why?
|
Chloroquine | 1 | 2021 | 280 | 0.170 |
Why?
|
Hospitalization | 7 | 2022 | 10232 | 0.170 |
Why?
|
Takotsubo Cardiomyopathy | 1 | 2021 | 125 | 0.170 |
Why?
|
China | 2 | 2022 | 2246 | 0.170 |
Why?
|
Smoking | 2 | 2016 | 8969 | 0.170 |
Why?
|
Meta-Analysis as Topic | 1 | 2023 | 1342 | 0.160 |
Why?
|
Ventricular Dysfunction, Left | 4 | 2019 | 2059 | 0.160 |
Why?
|
Puerperal Disorders | 1 | 2020 | 275 | 0.160 |
Why?
|
Acute Coronary Syndrome | 2 | 2021 | 2337 | 0.150 |
Why?
|
Prediabetic State | 1 | 2022 | 493 | 0.150 |
Why?
|
Hydroxychloroquine | 1 | 2021 | 408 | 0.150 |
Why?
|
Disclosure | 1 | 2023 | 736 | 0.140 |
Why?
|
Potassium | 1 | 2021 | 1336 | 0.140 |
Why?
|
Embolism | 1 | 2020 | 409 | 0.140 |
Why?
|
Pericardiocentesis | 2 | 2014 | 74 | 0.140 |
Why?
|
Heart Rate | 2 | 2017 | 4091 | 0.140 |
Why?
|
Brain Ischemia | 2 | 2023 | 3258 | 0.130 |
Why?
|
Sodium | 1 | 2021 | 1627 | 0.130 |
Why?
|
Quality Assurance, Health Care | 1 | 2006 | 2211 | 0.130 |
Why?
|
Heart Ventricles | 3 | 2017 | 3801 | 0.130 |
Why?
|
Patient Discharge | 3 | 2022 | 3300 | 0.130 |
Why?
|
Adiponectin | 1 | 2021 | 1099 | 0.130 |
Why?
|
Drug Combinations | 4 | 2022 | 1961 | 0.130 |
Why?
|
Follow-Up Studies | 9 | 2021 | 39004 | 0.120 |
Why?
|
Renal Insufficiency | 2 | 2014 | 802 | 0.120 |
Why?
|
Health Resources | 1 | 2021 | 911 | 0.120 |
Why?
|
Antimalarials | 1 | 2021 | 903 | 0.120 |
Why?
|
Transportation of Patients | 1 | 2014 | 185 | 0.110 |
Why?
|
Drug Therapy, Combination | 5 | 2022 | 6483 | 0.110 |
Why?
|
Pulmonary Wedge Pressure | 1 | 2014 | 264 | 0.110 |
Why?
|
Myocarditis | 1 | 2021 | 770 | 0.110 |
Why?
|
Stroke Volume | 6 | 2023 | 4983 | 0.110 |
Why?
|
Young Adult | 10 | 2021 | 56350 | 0.110 |
Why?
|
Tobacco, Smokeless | 1 | 2013 | 129 | 0.110 |
Why?
|
Endocarditis | 1 | 2016 | 348 | 0.100 |
Why?
|
Anticoagulants | 3 | 2022 | 4595 | 0.100 |
Why?
|
Heart Conduction System | 1 | 2017 | 1048 | 0.100 |
Why?
|
Health Personnel | 2 | 2023 | 3210 | 0.100 |
Why?
|
Age Distribution | 2 | 2014 | 2900 | 0.100 |
Why?
|
Health Surveys | 2 | 2020 | 4030 | 0.100 |
Why?
|
Rural Health | 1 | 2013 | 305 | 0.100 |
Why?
|
Decision Support Techniques | 1 | 2021 | 1952 | 0.100 |
Why?
|
Multicenter Studies as Topic | 3 | 2024 | 1661 | 0.090 |
Why?
|
Pericardial Effusion | 1 | 2012 | 246 | 0.090 |
Why?
|
Transients and Migrants | 1 | 2013 | 155 | 0.090 |
Why?
|
Risk Assessment | 7 | 2023 | 23320 | 0.090 |
Why?
|
Adolescent | 11 | 2023 | 85649 | 0.090 |
Why?
|
Bacterial Vaccines | 1 | 2012 | 402 | 0.090 |
Why?
|
Syphilis, Cardiovascular | 1 | 2009 | 2 | 0.090 |
Why?
|
Age Factors | 6 | 2021 | 18355 | 0.090 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2021 | 4414 | 0.090 |
Why?
|
Risk Reduction Behavior | 1 | 2016 | 1123 | 0.090 |
Why?
|
MEDLINE | 1 | 2009 | 125 | 0.090 |
Why?
|
Africa, Western | 2 | 2021 | 154 | 0.090 |
Why?
|
Patient Admission | 1 | 2016 | 1380 | 0.080 |
Why?
|
Disease | 1 | 2014 | 681 | 0.080 |
Why?
|
Malawi | 1 | 2009 | 281 | 0.080 |
Why?
|
Immunotherapy | 2 | 2014 | 4414 | 0.080 |
Why?
|
Survival Analysis | 3 | 2018 | 10248 | 0.080 |
Why?
|
Anemia | 1 | 2017 | 1499 | 0.080 |
Why?
|
MicroRNAs | 1 | 2024 | 3731 | 0.080 |
Why?
|
Hospitals, University | 1 | 2009 | 571 | 0.080 |
Why?
|
Single-Blind Method | 3 | 2019 | 1589 | 0.080 |
Why?
|
Cause of Death | 3 | 2021 | 3571 | 0.080 |
Why?
|
Survival Rate | 3 | 2017 | 12773 | 0.070 |
Why?
|
Genomics | 3 | 2024 | 5692 | 0.070 |
Why?
|
Anemia, Sickle Cell | 1 | 2014 | 1017 | 0.070 |
Why?
|
Ultrasonography, Doppler | 1 | 2008 | 458 | 0.070 |
Why?
|
Predictive Value of Tests | 6 | 2021 | 15056 | 0.070 |
Why?
|
Delivery of Health Care | 2 | 2022 | 5304 | 0.070 |
Why?
|
Reproducibility of Results | 3 | 2021 | 19862 | 0.070 |
Why?
|
Epidemiologic Studies | 1 | 2009 | 676 | 0.070 |
Why?
|
Sensitivity and Specificity | 2 | 2014 | 14720 | 0.070 |
Why?
|
Logistic Models | 3 | 2019 | 13403 | 0.060 |
Why?
|
Glucocorticoids | 1 | 2014 | 2107 | 0.060 |
Why?
|
Asia | 2 | 2016 | 607 | 0.060 |
Why?
|
Heart Atria | 2 | 2008 | 1348 | 0.060 |
Why?
|
Sex Factors | 3 | 2015 | 10392 | 0.060 |
Why?
|
Cohort Studies | 3 | 2022 | 40450 | 0.060 |
Why?
|
Time Factors | 5 | 2021 | 40054 | 0.060 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2018 | 3915 | 0.060 |
Why?
|
Hospital Mortality | 2 | 2015 | 5310 | 0.060 |
Why?
|
Incidence | 3 | 2021 | 20928 | 0.060 |
Why?
|
Primary Prevention | 1 | 2011 | 1166 | 0.060 |
Why?
|
Residence Characteristics | 1 | 2013 | 2049 | 0.060 |
Why?
|
Arginine | 1 | 2007 | 944 | 0.060 |
Why?
|
Rural Population | 1 | 2013 | 2207 | 0.060 |
Why?
|
Ventricular Function, Right | 2 | 2017 | 592 | 0.060 |
Why?
|
Thiazides | 1 | 2022 | 18 | 0.060 |
Why?
|
Coronavirus Infections | 1 | 2021 | 3130 | 0.050 |
Why?
|
Infant | 2 | 2022 | 35070 | 0.050 |
Why?
|
Environmental Exposure | 1 | 2017 | 4231 | 0.050 |
Why?
|
Systole | 2 | 2019 | 956 | 0.050 |
Why?
|
Qualitative Research | 2 | 2023 | 2680 | 0.050 |
Why?
|
South Africa | 2 | 2022 | 1728 | 0.050 |
Why?
|
Infarction | 1 | 2023 | 243 | 0.050 |
Why?
|
Health Expenditures | 1 | 2014 | 2346 | 0.050 |
Why?
|
Odds Ratio | 3 | 2021 | 9846 | 0.050 |
Why?
|
Inflammation | 1 | 2021 | 10578 | 0.050 |
Why?
|
Health Care Costs | 1 | 2014 | 3203 | 0.050 |
Why?
|
Treatment Outcome | 7 | 2022 | 62966 | 0.050 |
Why?
|
Potassium, Dietary | 1 | 2021 | 96 | 0.050 |
Why?
|
Genome-Wide Association Study | 2 | 2024 | 12220 | 0.050 |
Why?
|
Disease Progression | 2 | 2014 | 13256 | 0.050 |
Why?
|
Diastole | 3 | 2008 | 791 | 0.050 |
Why?
|
Hand Strength | 1 | 2023 | 444 | 0.050 |
Why?
|
Evidence-Based Medicine | 3 | 2018 | 3611 | 0.050 |
Why?
|
International Normalized Ratio | 1 | 2022 | 365 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 2 | 2024 | 17400 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 3 | 2016 | 6534 | 0.040 |
Why?
|
Observer Variation | 1 | 2006 | 2593 | 0.040 |
Why?
|
Heart Defects, Congenital | 1 | 2016 | 4566 | 0.040 |
Why?
|
Hemorrhage | 2 | 2022 | 3461 | 0.040 |
Why?
|
Calcium Channel Blockers | 1 | 2022 | 689 | 0.040 |
Why?
|
Retrospective Studies | 3 | 2022 | 77098 | 0.040 |
Why?
|
Fruit | 1 | 2024 | 1139 | 0.040 |
Why?
|
Vegetables | 1 | 2024 | 1179 | 0.040 |
Why?
|
Feeding Behavior | 2 | 2024 | 3187 | 0.040 |
Why?
|
Nitric Oxide | 1 | 2007 | 2128 | 0.040 |
Why?
|
Clergy | 1 | 2018 | 83 | 0.040 |
Why?
|
Sodium, Dietary | 1 | 2021 | 418 | 0.040 |
Why?
|
Angina, Unstable | 1 | 2021 | 926 | 0.040 |
Why?
|
Cerebral Infarction | 1 | 2022 | 1007 | 0.040 |
Why?
|
Child | 2 | 2022 | 77478 | 0.040 |
Why?
|
Awareness | 1 | 2021 | 639 | 0.040 |
Why?
|
Obesity | 2 | 2021 | 12705 | 0.030 |
Why?
|
Aftercare | 1 | 2022 | 860 | 0.030 |
Why?
|
Middle East | 1 | 2016 | 219 | 0.030 |
Why?
|
Enzyme Inhibitors | 1 | 2007 | 3800 | 0.030 |
Why?
|
Aged, 80 and over | 4 | 2018 | 57683 | 0.030 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 1517 | 0.030 |
Why?
|
Pregnancy Complications, Cardiovascular | 1 | 2020 | 501 | 0.030 |
Why?
|
Developed Countries | 1 | 2018 | 436 | 0.030 |
Why?
|
Apolipoprotein A-I | 1 | 2016 | 280 | 0.030 |
Why?
|
Waist-Hip Ratio | 1 | 2016 | 517 | 0.030 |
Why?
|
Pericarditis, Constrictive | 1 | 2014 | 42 | 0.030 |
Why?
|
Apolipoproteins B | 1 | 2016 | 373 | 0.030 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2009 | 11695 | 0.030 |
Why?
|
Primary Health Care | 1 | 2011 | 4551 | 0.030 |
Why?
|
Double-Blind Method | 2 | 2022 | 12017 | 0.030 |
Why?
|
Dyslipidemias | 1 | 2021 | 848 | 0.030 |
Why?
|
Warfarin | 1 | 2022 | 1493 | 0.030 |
Why?
|
Focus Groups | 1 | 2018 | 1320 | 0.030 |
Why?
|
Cardiac Tamponade | 1 | 2014 | 173 | 0.030 |
Why?
|
Obesity, Abdominal | 1 | 2016 | 361 | 0.030 |
Why?
|
Australia | 1 | 2016 | 1167 | 0.030 |
Why?
|
Pandemics | 2 | 2023 | 8328 | 0.030 |
Why?
|
England | 1 | 2014 | 523 | 0.030 |
Why?
|
Echocardiography, Doppler | 2 | 2008 | 934 | 0.030 |
Why?
|
Myocardial Contraction | 1 | 2017 | 1585 | 0.030 |
Why?
|
Penicillins | 1 | 2014 | 378 | 0.030 |
Why?
|
Health Education | 1 | 2018 | 1053 | 0.030 |
Why?
|
Family | 1 | 2023 | 3144 | 0.030 |
Why?
|
Disability Evaluation | 1 | 2019 | 1827 | 0.030 |
Why?
|
Organ Size | 2 | 2008 | 2253 | 0.020 |
Why?
|
Genetics, Medical | 1 | 2014 | 337 | 0.020 |
Why?
|
Health | 1 | 2014 | 390 | 0.020 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2014 | 780 | 0.020 |
Why?
|
Pilot Projects | 2 | 2014 | 8297 | 0.020 |
Why?
|
Ultrasonography | 3 | 2009 | 5978 | 0.020 |
Why?
|
Action Potentials | 1 | 2017 | 1814 | 0.020 |
Why?
|
Genetic Testing | 1 | 2023 | 3439 | 0.020 |
Why?
|
DNA | 1 | 2024 | 7289 | 0.020 |
Why?
|
Heart | 1 | 2023 | 4462 | 0.020 |
Why?
|
International Cooperation | 1 | 2016 | 1421 | 0.020 |
Why?
|
Europe | 1 | 2016 | 3339 | 0.020 |
Why?
|
Antibiotic Prophylaxis | 1 | 2014 | 638 | 0.020 |
Why?
|
Sex Distribution | 1 | 2014 | 2295 | 0.020 |
Why?
|
Ventricular Dysfunction, Right | 1 | 2014 | 578 | 0.020 |
Why?
|
Hospitals | 1 | 2023 | 3937 | 0.020 |
Why?
|
Diabetes Complications | 1 | 2016 | 1359 | 0.020 |
Why?
|
Body Surface Area | 1 | 2009 | 198 | 0.020 |
Why?
|
Pulmonary Artery | 1 | 2017 | 1911 | 0.020 |
Why?
|
Creatinine | 1 | 2014 | 1916 | 0.020 |
Why?
|
Seizures | 1 | 2021 | 2851 | 0.020 |
Why?
|
Pregnancy | 2 | 2020 | 29087 | 0.020 |
Why?
|
Treatment Failure | 1 | 2014 | 2615 | 0.020 |
Why?
|
Cardiomyopathy, Hypertrophic | 1 | 2017 | 1263 | 0.020 |
Why?
|
Blood Glucose | 1 | 2022 | 6249 | 0.020 |
Why?
|
Caregivers | 1 | 2018 | 2074 | 0.020 |
Why?
|
Administration, Oral | 1 | 2014 | 3913 | 0.020 |
Why?
|
Comorbidity | 1 | 2021 | 10372 | 0.020 |
Why?
|
Glomerular Filtration Rate | 1 | 2014 | 2167 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2018 | 3584 | 0.020 |
Why?
|
Poverty | 1 | 2018 | 2646 | 0.020 |
Why?
|
Biological Availability | 1 | 2007 | 396 | 0.020 |
Why?
|
Motor Activity | 1 | 2016 | 2714 | 0.020 |
Why?
|
Body Mass Index | 3 | 2009 | 12695 | 0.020 |
Why?
|
Diet | 1 | 2024 | 7923 | 0.020 |
Why?
|
Brachial Artery | 1 | 2007 | 370 | 0.020 |
Why?
|
Self Report | 1 | 2016 | 3548 | 0.020 |
Why?
|
Antitubercular Agents | 1 | 2012 | 1319 | 0.020 |
Why?
|
Health Behavior | 1 | 2016 | 2630 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2024 | 15494 | 0.020 |
Why?
|
Adrenal Cortex Hormones | 1 | 2012 | 1847 | 0.010 |
Why?
|
Brain | 2 | 2023 | 26343 | 0.010 |
Why?
|
Alcohol Drinking | 1 | 2016 | 3957 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2020 | 9941 | 0.010 |
Why?
|
Regional Blood Flow | 1 | 2007 | 1525 | 0.010 |
Why?
|
Body Height | 1 | 2009 | 1574 | 0.010 |
Why?
|
Vasodilation | 1 | 2007 | 944 | 0.010 |
Why?
|
Chronic Disease | 1 | 2017 | 9144 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2014 | 8621 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2018 | 5133 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2014 | 12344 | 0.010 |
Why?
|
Phenotype | 1 | 2017 | 16331 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2017 | 15530 | 0.010 |
Why?
|
Body Weight | 1 | 2009 | 4664 | 0.010 |
Why?
|
Reference Values | 1 | 2005 | 4982 | 0.010 |
Why?
|
Regression Analysis | 1 | 2007 | 6452 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2014 | 7153 | 0.010 |
Why?
|
Hemodynamics | 1 | 2006 | 4197 | 0.010 |
Why?
|
Endothelium, Vascular | 1 | 2007 | 4455 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2017 | 20086 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2005 | 12242 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2017 | 35342 | 0.010 |
Why?
|
HIV Infections | 1 | 2014 | 16678 | 0.000 |
Why?
|
United States | 1 | 2014 | 69693 | 0.000 |
Why?
|